IL112746A - Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride - Google Patents

Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride

Info

Publication number: IL112746A
Authority: IL; Israel
Prior art keywords: raloxifene; hydrochoride; pharmaceutical formulation; orally administrable; administrable pharmaceutical
Prior art date: 1994-03-02

Application number

IL11274695A

Other languages

English (en)

Other versions

IL112746A0 (en

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-02

Filing date

1995-02-23

Publication date

1999-12-31

1995-02-23 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1995-05-26 Publication of IL112746A0 publication Critical patent/IL112746A0/xx

1999-12-31 Publication of IL112746A publication Critical patent/IL112746A/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 title abstract 2
229960004622 raloxifene Drugs 0.000 title abstract 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
150000002148 esters Chemical class 0.000 abstract 1
150000002170 ethers Chemical class 0.000 abstract 1
239000012052 hydrophilic carrier Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

IL11274695A 1994-03-02 1995-02-23 Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride IL112746A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20491594A	1994-03-02	1994-03-02
SG1997000220A SG65636A1 (en)	1994-03-02	1997-01-30	Orally administrable pharmaceutical formulations

Publications (2)

Publication Number	Publication Date
IL112746A0 IL112746A0 (en)	1995-05-26
IL112746A true IL112746A (en)	1999-12-31

Family

ID=26665140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11274695A IL112746A (en)	1994-03-02	1995-02-23	Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride

Country Status (22)

Country	Link
EP (1)	EP0670162B1 (fr)
JP (1)	JP3574210B2 (fr)
CN (1)	CN1098684C (fr)
AT (1)	ATE211910T1 (fr)
AU (1)	AU684882B2 (fr)
BR (1)	BR9500758A (fr)
CA (1)	CA2143263C (fr)
CZ (1)	CZ286119B6 (fr)
DE (1)	DE69524981T2 (fr)
DK (1)	DK0670162T3 (fr)
ES (1)	ES2166799T3 (fr)
FI (1)	FI117042B (fr)
HU (1)	HU225418B1 (fr)
IL (1)	IL112746A (fr)
NO (1)	NO314286B1 (fr)
NZ (1)	NZ270588A (fr)
PL (1)	PL178858B1 (fr)
PT (1)	PT670162E (fr)
RU (1)	RU2118540C1 (fr)
SG (1)	SG65636A1 (fr)
SI (1)	SI0670162T1 (fr)
ZA (1)	ZA951497B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
CA2223595C (fr)	1995-06-07	2008-08-05	Neorx Corporation	Prevention et traitement de pathologies cardio-vasculaires au moyen d'analogues de tamoxifene
EA001257B1 (ru) *	1996-03-26	2000-12-25	Эли Лилли Энд Компани	Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием
US6458811B1 (en)	1996-03-26	2002-10-01	Eli Lilly And Company	Benzothiophenes formulations containing same and methods
ZA992858B (en)	1996-10-30	1999-07-29	Lilly Co Eli	Methods of preventing breast cancer.
CA2219377A1 (fr) *	1996-10-30	1998-04-30	Eli Lilly And Company	Ameliorations relatives a la prevention du cancer du sein
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) *	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
JP4798924B2 (ja) *	1999-12-13	2011-10-19	中外製薬株式会社	ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
EP1241158A4 (fr)	1999-12-13	2004-02-11	Chugai Pharmaceutical Co Ltd	Compose a chaine laterale hydroxycarbonyl-halogenoalkyle
RU2247106C2 (ru) *	1999-12-13	2005-02-27	Чугаи Сейяку Кабусики Кайся	Соединения с гидроксикарбонильными-галогеналкильными боковыми цепями
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos
JP4660067B2 (ja) *	2001-04-24	2011-03-30	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	抗血管新生剤とＴＮＦαとを用いる組合せ療法
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
EP1832583A1 (fr)	2002-09-30	2007-09-12	A/S GEA Farmaceutisk Fabrik	Nouveaux sels d'addition de l'acide raloxifène sulfurique et/ou leurs solvates et compositions pharmaceutiques les comprenant
US20050008704A1 (en) *	2003-07-11	2005-01-13	Ray Anup Kumar	Pharmaceutical composition for solubility enhancement of hydrophobic drugs
AU2007264418B2 (en)	2006-06-30	2012-05-03	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
WO2009049643A1 (fr) *	2007-10-16	2009-04-23	Pharmathen S.A.	Composition pharmaceutique améliorée contenant un modulateur de récepteur œstrogène sélectif, et procédé de préparation de celui-ci
EP2242483B1 (fr) *	2007-12-21	2013-02-20	Synthon B.V.	Composition de raloxifène
CN102438594A (zh)	2009-04-24	2012-05-02	伊休蒂卡有限公司	吲哚美辛的新剂型
WO2011000581A2 (fr) *	2009-07-02	2011-01-06	Synthon B.V.	Composition de raloxifène
WO2011099942A1 (fr)	2010-02-09	2011-08-18	Silverstone Pharma	Nouveaux sels d'addition de raloxifène, leur procédé de préparation et leur utilisation en thérapie
CN103006570B (zh) *	2012-10-08	2013-12-25	孙维会	一种阿佐昔芬速释微丸及其制备方法
US9561186B2 (en)	2012-11-30	2017-02-07	Pharmathen S.A.	Method for improving the bioavailability of low aqueous solubility drugs
CN103830197A (zh) *	2014-03-14	2014-06-04	崔书豪	一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
WO2018062964A1 (fr) *	2016-09-30	2018-04-05	한미약품 주식회사	Capsule composite contenant de la vitamine d ou un dérivé de celle-ci, et du raloxifène ayant un taux de dissolution amélioré, et son procédé de préparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

1995
- 1995-02-23 CA CA002143263A patent/CA2143263C/fr not_active Expired - Lifetime
- 1995-02-23 BR BR9500758A patent/BR9500758A/pt not_active Application Discontinuation
- 1995-02-23 IL IL11274695A patent/IL112746A/xx not_active IP Right Cessation
- 1995-02-23 ZA ZA951497A patent/ZA951497B/xx unknown
- 1995-02-24 CZ CZ1995499A patent/CZ286119B6/cs not_active IP Right Cessation
- 1995-02-24 RU RU95102924A patent/RU2118540C1/ru not_active IP Right Cessation
- 1995-02-27 CN CN95100822A patent/CN1098684C/zh not_active Expired - Lifetime
- 1995-02-28 PT PT95301291T patent/PT670162E/pt unknown
- 1995-02-28 DK DK95301291T patent/DK0670162T3/da active
- 1995-02-28 AT AT95301291T patent/ATE211910T1/de active
- 1995-02-28 EP EP95301291A patent/EP0670162B1/fr not_active Expired - Lifetime
- 1995-02-28 ES ES95301291T patent/ES2166799T3/es not_active Expired - Lifetime
- 1995-02-28 NZ NZ270588A patent/NZ270588A/en unknown
- 1995-02-28 SI SI9530581T patent/SI0670162T1/xx unknown
- 1995-02-28 DE DE69524981T patent/DE69524981T2/de not_active Expired - Lifetime
- 1995-03-01 AU AU13548/95A patent/AU684882B2/en not_active Expired
- 1995-03-01 HU HU9500635A patent/HU225418B1/hu not_active IP Right Cessation
- 1995-03-01 PL PL95307491A patent/PL178858B1/pl not_active IP Right Cessation
- 1995-03-01 FI FI950947A patent/FI117042B/fi not_active IP Right Cessation
- 1995-03-01 NO NO19950799A patent/NO314286B1/no not_active IP Right Cessation
- 1995-03-01 JP JP4177395A patent/JP3574210B2/ja not_active Expired - Lifetime
1997
- 1997-01-30 SG SG1997000220A patent/SG65636A1/en unknown

Also Published As

Publication number	Publication date
PL307491A1 (en)	1995-09-04
CZ286119B6 (cs)	2000-01-12
AU684882B2 (en)	1998-01-08
FI950947A0 (fi)	1995-03-01
CA2143263A1 (fr)	1995-09-03
JPH07277973A (ja)	1995-10-24
CZ49995A3 (en)	1995-10-18
NO314286B1 (no)	2003-03-03
NZ270588A (en)	1996-01-26
ZA951497B (en)	1996-08-23
HU9500635D0 (en)	1995-04-28
JP3574210B2 (ja)	2004-10-06
SI0670162T1 (en)	2002-06-30
CN1098684C (zh)	2003-01-15
NO950799L (no)	1995-09-04
CN1112420A (zh)	1995-11-29
ES2166799T3 (es)	2002-05-01
HUT72661A (en)	1996-05-28
DE69524981T2 (de)	2002-08-29
DK0670162T3 (da)	2002-03-11
BR9500758A (pt)	1995-10-24
DE69524981D1 (de)	2002-02-21
PL178858B1 (pl)	2000-06-30
FI117042B (fi)	2006-05-31
NO950799D0 (no)	1995-03-01
PT670162E (pt)	2002-06-28
SG65636A1 (en)	1999-06-22
EP0670162A1 (fr)	1995-09-06
CA2143263C (fr)	2002-01-08
FI950947L (fi)	1995-09-03
EP0670162B1 (fr)	2002-01-16
AU1354895A (en)	1995-09-07
IL112746A0 (en)	1995-05-26
HU225418B1 (en)	2006-11-28
RU2118540C1 (ru)	1998-09-10
ATE211910T1 (de)	2002-02-15

Legal Events

Date	Code	Title
1999-09-22	FF	Patent granted
2001-06-14	KB	Patent renewed
2006-01-15	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL112746A (en)	1999-12-31	Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
ZA926020B (en)	1993-03-10	Pharmaceutical combination formulation.
PH31205A (en)	1998-05-05	Pharmaceutical composition.
EP0634459A3 (fr)	1997-03-26	Formulations.
ZA917528B (en)	1993-03-22	Nasal pharmaceutical composition.
PL308416A1 (en)	1995-11-13	Stable protein containing lyophilised agent and dosing set therefor
AU6945491A (en)	1991-07-25	Pimobendan compositions
IE901821L (en)	1990-11-24	Porous pharmaceutical form
OA09810A (en)	1994-04-15	Pharmaceutical composition.
HU9402785D0 (en)	1994-12-28	Paramycin formulations for oral administration
EP0670166A3 (fr)	1996-06-12	Compositions pharmaceutiques administrables par voie buccale.
CA2203663A1 (fr)	1996-05-17	Compositions orales a liberation prolongee a base de cisapride
ZA92110B (en)	1993-07-08	Pharmaceutical compositions.
ZA927506B (en)	1993-05-03	New drug formulation.
ZA918381B (en)	1993-04-21	Pharmaceutical compositions.
IL110780A0 (en)	1994-11-11	Pharmaceutical compositions containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol for the treatment of the common cold
SI0835656T1 (en)	2002-08-31	Combination drug containing tramadol and a calcium channel antagonist
EP0419890A3 (en)	1991-05-29	Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
NZ228023A (en)	1991-10-25	24(r)-scymnol; preparatory processes and pharmaceutical compositions
ZA927369B (en)	1993-06-18	Pharmaceutical compositions.
MY117590A (en)	2004-07-31	Orally administerable pharmaceutical formulations
ZA92192B (en)	1993-07-12	Pharmaceutical compositions.
IT1273460B (it)	1997-07-08	Formulazioni farmaceutiche ad azione antivirale per uso topico
GB9020345D0 (en)	1990-10-31	Heteromonocyclic compounds,processes for the preparation thereof and pharmaceutical composition comprising the same
AU8086098A (en)	1998-11-19	Delta 12,13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them